Clinical Trial Update: Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase 2 trial of refametinib in RAS mutant hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Refametinib (refametinib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: COMPLETED